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Cancer Stem Cells (CSCs) are thought to be the cause of cancer initiation, growth and development. Thus, a 
challenge in cancer research is their identification and eradication. In our laboratory, by chemical treatment of the 
human osteosarcoma (OS) MG63 cell line, we have isolated and characterized 3AB-OS cells, a human OS CSC line. 
3AB-OS cells transdifferentiate in vitro into cells of the three derivatives germ layers and, when xenografted in athymic 
mice they are highly tumorigenic and recapitulate in vivo crucial features of human OS. They even express a 
reprogrammed energy metabolism, with a dependence on glycolytic metabolism more strong than parental MG63 
cells. 3AB-OS cells have chromosomes showing a great number of abnormalities which are very similar to 
abnormalities found in both pediatric and adult osteosarcomas. In comparison with parental MG63 cells (where TP53 
gene is hypermethylated, rearranged and in single copy), 3AB-OS cells have TP53 gene unmethylated, rearranged and 
in multiple copies. Moreover, the mutp53 (p53-R248W/P72R) is post-translationally stabilized, has nuclear localization 
and a gain of function. A great number of results obtained in our laboratories suggested that p53 mutation could be the 
“driver mutation” at the origin of the transformation of MG63 cells into 3AB-OS CSCs. 
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Cancer can develop in anyone with the risk of having a 
cancer increasing with age. Thus cancers are more 
numerous in adults, with 77% of them being diagnosed in 
persons older than 55 years of age 
[1]
. Overall, death from 
cancer in the US accounts for about 20% of death 
[2]
. The 
largest number of cancer patients live in low- and 
middle-income countries, where the medical resources 
and health systems are unable to coping with the disease. 
This is exacerbated by the evidence that the health burden 
of cancer grows in parallel with the population aging, in 
such a way that in 2030 more that 20 million new cancer 
cases are expected, accompanied by about 13 million of 
cancer deaths 
[3]
. Terribly, the future may be much worse 
because of the lifestyles associated with urbanization and 
economic development (physical inactivity, smoking, 
environmental deterioration) in low- and middle-income 
countries. Thus, the most important challenge for cancer 
researchers is to reduce the enormous burden of cancer 
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on public health. 
Osteosarcoma (OS) is the most common bone cancer. 
Most osteosarcomas are treated with chemotherapy given 
before surgery (neoadjuvant chemotherapy) for about 10 
weeks, followed by local tumor control (surgery and/or 
radiation) and, after that, again by chemotherapy 
(adjuvant chemotherapy) for up to a year. Currently,with 
the standard chemotherapy (cisplatin, doxorubicin and 
methotrexate) only 65-70% OS patients has a long-term 
survival disease-free without metastasis 
[4]
, and in 
addition, for relapsed OS there is no second-line 
chemotherapy. The survival rates have essentially 
plateaued over the last several decades, particularly for 
patients with metastatic disease. Despite efforts to 
intensify therapy through dosing, timing or ablation, 
improvements have been limited. Thus efforts are 
currently focused on understanding the molecular and 
cellular mechanisms and signaling pathways involved in 
the pathogenesis and metastasis of OS in order to devise 
more rationale, targeted therapies aimed at improving 
long term patient survival.  
It is known that solid tumors are organized 
hierarchically and that a distinct subpopulation of cells, 
termed cancer stem cells (CSCs), is at the root of their 
growth 
[5]
, as they are responsible for tissue renewal, 
malignancy and resistance to therapies. However, still 
now the origin of CSCs is an outstanding issue, indeed it 
is not known whether CSCs arise from transformed stem 
cells or whether cancer cells are progressively 
transformed in CSCs. Anyway, it is certain that CSCs are 
present in the majority of tumors where they contribute to 
the initiation and development of the cancer 
[6]
. 
According to this knowledge, a fundamental problem in 
the research on OS is the identification of the CSCs 
within the cancer cell population with the aim of their 
eradication.  
A human OS CSC line (3AB-OS) has been produced 
and isolated for the first time in our laboratory from the 
human osteosarcoma MG63 cell line by chemical 
treatment 
[7]
. In this regard, we first showed that treating 
for a short time (24-72 h) MG63 cells with a competitive 
inhibitor of poly (ADP-ribose) polymerase, the 
3-aminobenzamide (3AB), their growth rate resulted 
markedly reduced and this was accompanied by osteocyte 
differentiation 
[8]
. We also observed that osteocyte 
differentiation was accompanied by reprogrammed gene 
expression, with down-regulation of genes required for 
proliferation and up-regulation of those implicated in 
osteoblastic differentiation 
[9]
. Thereafter, studying the 
effects of the 3AB treatment for longer times (about 100 
days) we observed the death of osteocyte cells with a 
simultaneous and progressive enrichment of a new, stable 
cell population, termed 3AB-OS. The characterization of 
3AB-OS cells demonstrated that they are a heterogeneous 
and stable cell population. Indeed, after serial passages 
(currently, more than 200) in the absence of 3AB this cell 
population retained all morphological and antigenic 
features. Importantly, 3AB-OS cells show unlimited 
proliferative potential, ABCG2-dependent phenotype 
with high drug efflux capacity, strong expression of 
stemness and antiapoptotic genes which are the most 
important features of CSCs 
[7]
.  
Multilineage differentiation potential is the important 
characteristic of CSCs, and there is now increasing 
evidence that microenvironments play critical roles in the 
behavior of stem cells, especially in deciding their 
differentiation directions 
[10]
. Aimed at understanding the 
level of stemness of 3AB-OS CSCs, we showed that they 
are highly aggressive; placed in plates characterized by 
ultralow-attachment, they grow at a low density with a 
high sphere-formation efficiency 
[7]
. They also penetrate 
Matrigel with an invasion ability which was 2.6-fold 
higher than parental MG63 cells. We even showed that 
3AB-OS cells transdifferentiate, in vitro, into cells of 
ectodermal, endodermal and mesodermal germ layers and 
that each of they showed specific morphological and 
functional properties 
[11]
. When xenografted in athymic 
mice in the presence of matrigel, 3AB-OS cells were 
highly tumorigenic and induced the formation of a great 
number of blood vessels; they also showed multilineage 
commitment particularly favoring the mesenchymal 
lineage, with activation of myoblast differentiation and 
with the appearance of muscle fibers in the tumor mass. 
Overall, for the first time we provided a mouse model 
which recapitulate in vivo the key aspects of human 
osteosarcoma CSCs. Using this animal model, the 
efficacy in vivo of novel therapeutic treatments could be 
tested and predicted. Our results suggest that 3AB-OS 
cells behavior might be regulated by matrigel interaction 
with subcutaneous microenvironment, with such 
interaction providing the adequate cues for transducing 
signals either oncogenic or differentiative 
[12]
. 
It is maintained that all cancers result from a process 
of Darwinian evolution developed among cell 
populations surrounded by various microenvironments 
provided by the tissues of a multicellular organism 
[13]
. 
Similarly to the Darwinian evolution supporting the 
origins of species, cancer is assumed to originate by 
acquisition of genetic variation determined by random 
mutation in individual cells and by natural selection of 
the phenotypic diversity resultant by these mutations. 
Cells carrying deleterious mutations may be uprooted by 
natural selection, whereas cells carrying mutations 
conferring capability to proliferate and survive more 
efficiently than others may be favored. When casually a 
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single cell acquires a number of favorable mutations, this 
will allow the cell to proliferate autonomously, invade 
and metastasize 
[13]
. During the multistep development of 
human tumors, the cells acquire a number of biological 
capabilities (uninterrupted proliferative signaling, evasion 
of growth suppressors, cell death resistance, replicative 
immortality, angiogenesis induction, invasion and 
metastasis activation) which are recognized as cancer 
superpowers or hallmarks 
[14]
. The acquisition of these 
hallmarks is enabled by genomic instability, which in 
turn generates the genetic diversity that accelerates their 
acquisition. Recently, an emerging hallmark has been 
identified in the “reprogramming energy metabolism”, a 
series of adjustments of energy metabolism aimed at 
fueling cell growth and division. It may not be surprising 
that growing tumors, which have potent increases in cell 
proliferation accompanied by environmental fluctuations 
in nutrient and oxygen availability, display significant 
changes in pathways of energy metabolism and nutrient 
uptake. The first observation that tumor cells, to produce 
ATP from glucose, prefer to use glycolysis instead than 
oxidative phosphorylation, was made by Otto Warburg 
which suggested that defects in mitochondrial function, 
could be at the root of cancer 
[15]
. Glycolytic fueling has 
been shown to be associated with mutations in tumor 
suppressors genes (e.g., TP53), whose alterations in 
tumor cells are selected as they avoids cytostatic controls, 
and attenuates apoptosis, thus conferring the hallmark 
capabilities for cell proliferation
 [16]
. Recently, 
bioenergetics studies have revealed that human ESCs 
depend on glycolysis for ATP production 
[17]
. 
Consistently, mitochondria are less complex and fewer in 
number in human ESCs than in their differentiated 
progeny, and it has been shown that a glycolytic 
engagement is a crucial step in the conversion of 
terminally differentiated cells into iPSCs 
[18]
. However, 
still now it is not known whether metabolic shifts precede 
pluripotency acquisition or stem cell state promote 
changes in metabolism. It has been suggested that during 
reprogramming a positive feedback loop is initiated, in 
which transcription factors first elicit a metabolic shift 
that is then necessary to induce additional endogenous 
pluripotency factors to complete the reprogramming into 
a stem cell state 
[19]
. Overall, these results suggest that 
tumor bioenergetics and CSCs might be related to each 
other. To characterize the energetic properties of 
3AB-OS CSCs, we analyzed their bioenergetics features 
comparatively with that of the parental more differentiate 
MG63 OS cells. Our results demonstrated that 3AB-OS 
cells depend on glycolytic metabolism more strongly than 
MG63 cells. Moreover, 3AB-OS cells show lower levels 
of mitochondrial respiration, are more sensitivity to 
glucose depletion or glycolytic inhibitors and show a 
reduced sensitivity to inhibitors of oxidative 
phosphorylation. In addition, with respect to MG63 cells, 
3AB-OS have fragmented mitochondria which rapidly 
networked in the presence of glucose-rich medium, 
whereas, growing in low glucose they entirely lose these 
structures. Overall, the findings suggested that the energy 
metabolism of 3AB-OS CSC strongly resemble that of 
normal stem cells and cancer cells which are 
characterized by a glycolytic anaerobic metabolism
 [20]
. 
Cancer cells have multiple genetic/epigenetic changes 
responsible for chromosomal instability and tumor 
progression 
[21]
. These mechanisms involve aberrations 
with loss or gain of genes function that mostly impinge 
on tumor suppressors. In our laboratories we have shown 
that 3AB-OS cells have large chromosomal complexity 
and molecular abnormalities which are present in the 
most aggressive human cancers. 3AB-OS cells have a 
hyper triploid karyotype and chromosome number 
ranging from 71 to 82, whereasMG63 cells have a 
hypotriploid karyotype and chromosome number ranging 
from 61 to 66. Moreover, 3AB-OS cells show 
monosomies, trisomies and nullisomies, have 32 
unidentifiable marker chromosomes, and exhibit -with 
respect to parental MG63 cells- 49 copy number 
variations (gains/losses) affecting almost all the 
chromosomes 
[22]
. Intriguingly, the abnormalities 
evidenced in 3AB-OS cells are very similar to those 
described in a large number of pediatric and adult 
osteosarcomas, where karyotypes ranging from haploid to 
near hexaploid have been shown 
[23-25]
. Moreover, 
3AB-OS cells showed losses/gains in agreement with 
those seen in osteosarcoma patients 
[23-25]
. Comparing 
3AB-OS cells to MG63 cells we reported the gene 
expression profile of 3AB-OS cells. In addition, 
employing KEGG and BioCarta analysis, we selected 
196 genes which resulted up-/down-regulated and which 
appeared to be involved in regulatory pathways of 
tumorigenesis and stemness (ECM-receptor interaction 
and cell communication; cell adhesion molecules; ABC 
transporters in general; Notch and Hedgehog signaling; 
MAPK signaling; cell cycle regulators; apoptosis) most 
of which have been reported in osteosarcoma patients 
[26]
. 
In addition, by human MicroRNA array analyses we 
identified 189 differentially expressed miRNAs and the 
analysis of mRNA/miRNA expression profiles appeared 
to be very similar to those reported in human OS patients 
[27, 28]
. Furthermore, to define a surface protein signature 
specific for 3AB-OS CSCs and MG63 cells, we have 
used cytometric analysis with an antibody-array 
comprising 245 membrane proteins. We also selected 
MAPK/ERK1/2 as a potential protein kinase-pathway 
correlated with pathways that characterize tumorigenesis 
and stemness of 3AB-OS cells 
[29]
. 
More than half of all cancers exhibit mutation at p53 
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locus on the short arm of chromosome I7 at I7p13 
[30]
. As 
a consequence, the most important tumor suppressor 
(p53) results altered in its functions as it may result either 
mutated or lost. Wild-type human p53 transcriptionally 
targets a large number of genes which mediates cell cycle 
arrest, DNA repair, senescence, apoptosis, and various 
metabolic processes. Thus, the loss of p53 function has 
been usually associated with an impairment of these 
functions 
[31]
. TP53 missense mutations represent the 
majority of cancer-associated mutations which lead to the 
expression of a full-length altered p53 protein which, in 
contrast to wild-type p53, has a prolonged half-life. 
These missense mutations even determine oncogenic or 
gain-of-function activity 
[32, 33]
. Moreover, the presence of 
mutant p53 with gain of functions introduces new 
components which activate cancer progression and 
aggressiveness 
[34, 35]
. Most recently 
[36]
, our studies on 
TP53 gene status/role performed in the highly aggressive 
3AB-OS CSC line, have shown its involvement in 
promoting proliferation, invasiveness, resistance to 
apoptosis and stemness. In particular, we have shown 
that, in comparison with parental MG63 cells (where 
TP53 gene is hyper methylated, rearranged and in single 
copy), 3AB-OS cells have TP53 gene unmethylated, 
rearranged and in multiple copies. Moreover, mutp53 
(p53-R248W/P72R) is post-translationally stabilized and 
with nuclear localization. Interestingly, 
p53-R248W/P72R-knockdown by short-interfering RNA, 
reduced the growth and replication rate of 3AB-OS cells, 
markedly increasing cell cycle inhibitor levels and 
sensitizing 3AB-OS cells to TRAIL-induced apoptosis; in 
addition, the knockdown strongly decreased the levels of 
stemness and invasiveness genes; finally, the ectopic 
expression of p53-R248W/P72R in parental MG63 cells 
promoted cancer stem-like features (high proliferation 
rate, sphere formation, clonogenic growth, high migration 
and invasive ability) and strongly increased the levels of 
stemness proteins (CD133, ABCG2, Nanog, OCT3/4, 
Nucleostemin, Sox2). Overall, the findings suggested that 
p53 mutation could be the “driver mutation” at the origin 
of the dedifferentiation of MG63 cells into 3AB-OS 
CSCs. 
Currently, we are working at the following purposes: 
1) we have previously described in 3AB-OS CSCs a 
predictive network for let-7/98 and miR-29a, b, c, (two 
deeply down regulated miRNA family) and MSTN, 
CCND2, Lin28B, MEST, HMGA2, GHR (their 
anticorrelated and highly up regulated mRNAs). These 
miRNAs/mRNAs may represent new biomarkers for OS 
and permit the identification of new potential therapeutic 
targets 
[22]
. Now, we have singularly over expressed these 
miRNAs in 3AB-OS cells and we are aimed at studying 
their effects on 3AB-OS stemness and behaviour. To do 
this, we will subcutaneously xenograft athymic nude 
mice, separately, with each of the 3AB-OS clones 
overexpressing these miRNAs, in comparison with mice 
xenografted with parental 3AB-OS cells; 2) because we 
think that p53 mutation could be the “driver mutation” at 
the root of the dedifferentiation of MG63 cells into 
3AB-OS CSCs 
[36]
, we are producing, by stable RNAi 
system, a 3AB-OS cell line that does not express mutant 
p53. We aim to evaluate whether the 3AB-OS cells 
lacking the mutant p53, undergo morphological, 
molecular and fuctional changes; 3) it is easily 
conceivable that the multipotent phenotype of CSCs can 
simultaneously detect and integrate multiple signals from 
their microenviroment and convert them to a coherent 
environmental signal to regulate the downstream gene 
expression and stem cell fate 
[10]
. Given the pluripotent 
ability evidenced in vitro by 3AB-OS CSCs, we will 
inoculate these cells in various heterotopic sites in 
athymic nude mice, aimed at evaluating whether the 
microenvironment is critical for CSCs in deciding 
differentiation directions. 
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